# Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

> **NCT01770379** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 242 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Secukinumab (AIN457)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01770379
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2016-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01770379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01770379, "Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01770379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*